US FDA warns against design complacency:
This article was originally published in Clinica
The FDA has warned US companies not to be complacent about design control requirements despite having a one-year grace before they become fully implemented in June 1998. Speaking at an FDA/Food and Drug Law Institute conference last week, FDA quality system expert, Kim Trautman, told companies they needed to make good use of this grace period to "fine-tune their design control systems". Last week the FDA issued a final guidance document on its design control rules.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?